Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity

Keywords

Folinic acid, Fluorouracil, Cytotoxicity, Topoisomerase, Chemistry

References

• Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.Jessica Conti, Nancy E. Kemeny, Leonard B. Saltz — 1996
• Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.Scott H. Kaufmann, JE Karp, R. G. Wyn Jones — 1994
• The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluorodeoxyuridine, and 3-deazauridine.Robert Jackson — 1978
• Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.Eric K. Rowinsky, L B Grochow, D S Ettinger — 1994
• Additional members of the rat liver lamin polypeptide family. Structural and immunological characterization.Scott H. Kaufmann — 1989
• ICI D1694 and idoxuridine: a synergistic antitumor combination.Josie Pressacco, David W. Hedley, Charles Erlichman — 1994
• Regulation of thymidylate synthetase in mouse leukemia cells (L1210).Wojciech Rode, Kevin J. Scanlon, Barbara A. Moroson — 1980
• Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue.P. G. Johnston, Chen Liang, Sylvie Henry — 1991
• Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Mace L. Rothenberg, John R. Eckardt, John G. Kuhn — 1996
• Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.Leonard B. Saltz, Jane Kanowitz, Nancy E. Kemeny — 1996
• Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*)Stacie J. Froelich-Ammon, Neil Osheroff — 1995
• SV40 DNA replication intermediates: Analysis of drugs which target mammalian DNA replicationRobert M. Snapka, Paskasari A. Permana — 1993
• In vitro assays for antitumour activity: more pitfalls to come?A.-R. Hanauske — 1993
• Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival.Maria Cristina Pagliacci, Fabrizio Spinozzi, Graziella Migliorati — 1993
• CPT-11 (irinotecan) in the treatment of colorectal cancer.Jean‐Pierre Armand, Michel Ducreux, M. Mahjoubi — 1995
• Different drugs arrest cells at a number of distinct stages in G2Robert A. Tobey — 1975
• DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathwaysWilliam G. Nelson, Michael B. Kastan — 1994
• The current status of camptothecin analogues as antitumor agents.William J. Slichenmyer, Eric K. Rowinsky, Ross C. Donehower — 1993
• Effects of CPT‐11 in combination with other anti‐cancer agents in cultureYasuhiko Kano, Kenichi Suzuki, Miyuki Akutsu — 1992
• A phase-I study of cpt-11, weekly bolus 5-fu and leucovorin in patients with metastatic cancer.Parnes Hl, Nancy Tait, Barbara A. Conley — 1995

Cited by

• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.Thierry Conroy, Françoise Desseigne, Marc Ychou — 2011
• Participación de p19INK4d en la inducción de senescencia genotóxica y replicativaSilvina V. Sonzogni — 2012
• The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.Bridget A. Quinn, Nathaniel A. Lee, Timothy P. Kegelman — 2015
• Prolonging the exposure to anti-cancer agentsOtto Soepenberg — 2004
• A importância da seqüência de administração do irinotecan e 5-fluorouracil na inibição da proliferação do carcinoma de cólon humano in vitroIvana Grivicich — 1999
• Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer – a phase II studyShannon K Tomlinson, Susan A. Melin, Vetta Higgs — 2002
• Irinotecan in the treatment of colorectal cancer: clinical overview.U. Vanhoefer, A. Harstrick, W. Achterrath — 2001
• Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.Alfredo Falcone, Antonello Di Paolo, Gianluca Masi — 2001
• A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center ExperienceSoon Il Lee, Se Hoon Park, Do Hyoung Lim — 2011
• Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal CancerMay Mabro, Christophe Louvet, Thierry André — 2003
• Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOXF. Recchia, Gaetano Saggio, Antonio Nuzzo — 2004
• Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogsDonna Voeller, Jean L. Grem, Yves Pommier — 2000
• The relevance of drug sequence in combination chemotherapy.Manish A. Shah, Gary K. Schwartz — 2000
• CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.Thierry André, Christophe Louvet, F Maindrault-Goebel — 1999
• Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancerHitoshi Kusaba, Taito Esaki, Junji Kishimoto — 2012
• Preclinical Evaluation of IrinotecanU. Vanhoefer, W. Achterrath, H. Wilke — 2000
• Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric CancerHui Luo, Zhiqiang Wang, Feng-Hua Wang — 2011
• A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancerSang Cheul Oh, Halil Yılmaz Sur, Hwa Jung Sung — 2007
• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell lineYasuhiro Inoue, Chikao Miki, Hideki Watanabe — 2007
• Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancerHiromitsu Fujishima, Ikuo Kikuchi, O Miyanaga — 2004

Related papers

• Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.E Bobbio-Pallavicini, Camillo Porta, Mauro Moroni — 1993
• [Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04].Katja Schumacher — 2000
• Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.Doroshow Jh, M Bertrand, Edward M. Newman — 1987
• Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-FluorouracilMarkus Moehler, F. Gutzler, Silke Steinmann — 2003
• A Phase II Study of 5‐Fluorouracil Plus High‐Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung CancerDavid J. Stewart, Simone Dahrouge, Katherine M. Soltys — 1995
• Severe central nervous system toxicity associated with continuous infusion of 5-fluorouracilDanxia Lin — 2004
• Phase II study of 24 hours-infusion of 5-fluorouracil and high dose folinic acid in patients with progressive or recurrent colorectal cancer (CRC)Julia Hartmann, Claus Henning Köhne, Hans‐Joachim Schmoll — 1997
• Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combinationThierry Delaunoit, Raphaël Maréchal, Alain Hendlisz — 2004
• Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.Moran Rg, Scanlon Kl — 1991